The DCVax-L TLD hasn't been reviewed by ANY credible source -- not any regulator, nor any peer-reviewers for a journal. Although they can blow smoke with reviewers by not giving them all the data or the full story of the original protocol and failed PFS primary endpoint.
The only credible source that counts are the regulators -- that's why they have to do a large-scale, well-controlled clinical trial.
Sawston has nothing to do with the efficacy or safety of DCVax-L. NICE has been notoriously resistant to paying for high priced oncology drugs. But first MHRA has to approve it for commercial sale in UK. Canada is also the same.
Market Data 
Markets 
AI
